Evotec SE (EVO) Cash from Investing Activities (2009 - 2026)
Evotec SE (EVO) reported Cash from Investing Activities of -$14557.1 for Q1 2026, up 35.95% on a YoY basis from -$10707.6 in Q1 2025, and down 100.01% sequentially from $199.8 million in Q4 2025.
Evotec SE (EVO) Cash from Investing Activities (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 9 years of Cash from Investing Activities data on file, last reported at -$14557.1 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 35.95% year-over-year to -$14557.1; the trailing twelve-month figure through Mar 2026 stood at $199.8 million (up 362.62% YoY), and the FY2025 full-year result was $199.7 million, up 362.57% from the prior year.
- Cash from Investing Activities retreated to -$14557.1 in Q1 2026, from $199.8 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $199.8 million in Q4 2025 to a low of -$420.7 million in Q4 2022.
- A 5-year average of -$18.3 million and a median of -$28464.8 in 2024 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities plunged 191439.37% in 2022 and surged 362.98% in 2025, its largest moves.
- Tracing EVO's Cash from Investing Activities over 5 years: stood at -$420.7 million in 2022, then jumped by 96.6% to -$14.3 million in 2023, then sank by 430.62% to -$76.0 million in 2024, then surged by 362.98% to $199.8 million in 2025, then sank by 100.01% to -$14557.1 in 2026.
- Business Quant data shows EVO's Cash from Investing Activities at -$14557.1 in Q1 2026, $199.8 million in Q4 2025, and -$8465.1 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.55 Bn | 87.69 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.45 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.47 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Evotec SE | 345.39 Mn | 344.87 Mn | - | -14,557.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,557.05 |
| Mar 31, 2026 | -14,557.05 |
| Dec 31, 2025 | 199.80 Mn |
| Dec 31, 2025 | 199.80 Mn |
| Sep 30, 2025 | -8,465.13 |
| Sep 30, 2025 | -8,465.13 |
| Jun 30, 2025 | -24,838.59 |
| Jun 30, 2025 | -24,838.59 |
| Mar 31, 2025 | -22,728.07 |
| Mar 31, 2025 | -22,728.07 |
| Dec 31, 2024 | -75.98 Mn |
| Dec 31, 2024 | -75.98 Mn |
| Sep 30, 2024 | -28,464.75 |
| Sep 30, 2024 | -28,464.75 |
| Jun 30, 2024 | -33,687.20 |
| Jun 30, 2024 | -33,687.20 |
| Mar 31, 2024 | -33,576.18 |
| Mar 31, 2024 | -33,576.18 |
| Dec 31, 2023 | -14.32 Mn |
| Dec 31, 2023 | -14.32 Mn |